article thumbnail

Tofersen

New Drug Approvals

3] Tofersen was approved for medical use in the United States in April 2023, [3] [6] and in the European Union in May 2024. [4] 25 April 2023. Archived from the original on 8 May 2023. Retrieved 10 June 2023. 25 April 2023. Archived from the original on 25 April 2023. Retrieved 25 April 2023.

article thumbnail

Protein degraders: chasing undruggable targets

BioPharma Drive: Drug Pricing

Published July 8, 2025 Gwendolyn Wu Senior reporter post share post print email license Proteasomes are cellular machines for breaking down proteins. Crews, in 2023, helped launch Halda Therapeutics , which is testing a spin on induced proximity by getting one protein to “smother” the other.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vamorolone

New Drug Approvals

10] Vamorolone was approved for medical use in the United States in October 2023, [11] [10] and in the European Union in December 2023. [2] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age. 2] Vamorolone was approved for medical use in the European Union in December 2023.

FDA
article thumbnail

Elacestrant 

New Drug Approvals

2] Elacestrant was approved for medical use in the United States in January 2023, [1] [2] [5] [6] and in the European Union in September 2023. [3] 2] Elacestrant was approved for medical use in the United States in January 2023, [1] [2] [5] [6] and in the European Union in September 2023. [3] 8 February 2023.

FDA
article thumbnail

Gepirone

New Drug Approvals

4] It was approved for the treatment of major depressive disorder in the United States in September 2023. [4] 5] History Gepirone was developed by Bristol-Myers Squibb in 1986, [5] but was out-licensed to Fabre-Kramer in 1993. 4] It was approved for the treatment of major depressive disorder in the United States in September 2023. [4]

FDA
article thumbnail

Inavolisib

New Drug Approvals

Retrieved 21 September 2023. Retrieved 21 September 2023. Retrieved 21 September 2023. ^ April 2023). Retrieved 21 September 2023. Retrieved 21 September 2023. World Health Organization (2023). PMID 36455032. S2CID 254149451. ^ “CID 124173720, Inavolisib” PubChem. 1 October 2024.

FDA
article thumbnail

Zilucoplan

New Drug Approvals

11] Zilucoplan was approved for medical use in the United States in October 2023, [6] [12] in the European Union in December 2023, [7] and in Australia in July 2024. [1] 11] Zilucoplan was approved for medical use in the United States in October 2023, [6] [12] in the European Union in December 2023, [7] and in Australia in July 2024.

FDA